Estimating the risks and benefits before salvage surgery for recurrent head and neck squamous cell carcinoma
Estimating the risks and benefits before salvage surgery for recurrent head and neck squamous cell carcinoma
复制标题
DOI:
10.1016/j.ejso.2021.01.022
复制
发表时间:
2021-06-14
期刊:
影响因子:
3.8
通讯作者:
Dolivet, Gilles
中科院分区:
文献类型:
--
作者:
Locatello, Luca Giovanni;Mastronicola, Romina;Dolivet, Gilles
Introduction: The risks associated with salvage surgery of head and neck squamous cell carcinoma (SCC) in a previously irradiated field needs to be balanced against the expected survival benefits. We want to identify preoperative predictive factors for overall and disease-specific survival (OS/DSS) and for the development of serious (Clavien-Dindo, CD>III) complications following salvage surgery for radio-recurrent SCC to help surgeons, patients, and caregivers in the decision-making process in this setting.Materials and methods: The records of 234 patients presenting to the Lorraine Cancer Institute with locoregional radiorecurrent SCC were reviewed. The primary endpoint was OS, secondary endpoints were DSS, OS without tracheostomy/gastrostomy, and the risk of CD>III complications. Multivariate analyses were carried out to explore preoperative factors associated with survival and the risk of post -operative complications.Results: With a median follow-up time of 19 months, 5-year OS since the first salvage surgery was 28.3%, 5-year DSS was 38.9%. 2-and 5-year functional OS were 45.6% and 27.2%. rcT-rcN, and WUNHCI >4 were both independent significant preoperative predictors of OS and DSS. 30-days postoperative complica-tions occurred in 44.4% of patients (28 CD I, 24 CD II, 34 CD III, 11 CD IV, 7 CD V). A salvage procedure involving T+N plus the presence of a WUHNCI >4 was the only independent predictor of CD>III complications.Conclusion: When discussing with the patients and the caregivers salvage surgery for recurrent head and neck SCC, a careful evaluation of the preoperative comorbidities by the WUHNCI tool can reliably predict the expected risks and benefits from the procedure.(c) 2021 Elsevier Ltd, BASO -The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.